RBC Capital Maintains Sector Perform on Spruce Biosciences, Lowers Price Target to $0.5

Benzinga · 04/16 15:35
RBC Capital analyst Gregory Renza maintains Spruce Biosciences (NASDAQ:SPRB) with a Sector Perform and lowers the price target from $1.5 to $0.5.